Lung adenocarcinoma in a patient with Lynch syndrome: a case report and literature review

被引:0
作者
Hodges, Alan [1 ,2 ]
Sun, Kai [3 ]
Sheu, Tiffany G. [4 ]
Bernicker, Eric H. [3 ]
机构
[1] Texas A&M Sch Med, Bryan, TX USA
[2] Houston Methodist Res Inst, Ctr Immunotherapy Res, Houston, TX USA
[3] Houston Methodist Neal Canc Ctr, Houston, TX 77479 USA
[4] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX USA
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
Lynch syndrome; NSCLC; MLH1; immune checkpoint therapy; ctDNA; MICROSATELLITE INSTABILITY; CHECKPOINT INHIBITORS; COLORECTAL-CARCINOMA; CANCER; TUMORS; PEMBROLIZUMAB; INSIGHTS; SURGERY;
D O I
10.3389/fonc.2023.1193503
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This article presents a case of a 62-year-old Vietnamese woman with a history of Lynch syndrome (LS), who developed lung adenocarcinoma with EGFR L858R mutation. LS is an autosomal dominant cancer predisposition syndrome caused by a pathogenic germline variant in DNA mismatch repair genes, often leading to microsatellite instability. While LS is primarily associated with gastrointestinal, endometrial, ovarian, and urologic tract cancers, lung cancer accounts for less than 1% of LS-related cancers, with only six cases of LS-related lung cancer previously reported in the literature. The patient underwent multiple lines of treatment for her lung adenocarcinoma, including tyrosine kinase inhibitors, stereotactic body radiation therapy, pemetrexed and pembrolizumab, amivantamab, and fam-trastuzumab deruxtecan, but all resulted in only a partial response followed by a progressive disease. This case highlights the complex interplay of genetic cancer predisposition syndromes and the development of spontaneous driver mutations in the disease course and the subsequent management of tumors arising in these patients.
引用
收藏
页数:6
相关论文
共 33 条
  • [1] Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer
    Aggarwal, Charu
    Thompson, Jeffrey C.
    Black, Taylor A.
    Katz, Sharyn I.
    Fan, Ryan
    Yee, Stephanie S.
    Chien, Austin L.
    Evans, Tracey L.
    Bauml, Joshua M.
    Alley, Evan W.
    Ciunci, Christine A.
    Berman, Abigail T.
    Cohen, Roger B.
    Lieberman, David B.
    Majmundar, Krishna S.
    Savitch, Samantha L.
    Morrissette, Jennifer J. D.
    Hwang, Wei-Ting
    Elenitoba-Johnson, Kojo S. J.
    Langer, Corey J.
    Carpenter, Erica L.
    [J]. JAMA ONCOLOGY, 2019, 5 (02) : 173 - 180
  • [2] Bari S, 2020, J CLIN ONCOL, V38
  • [3] Synchronous lung tumours in a patient with metachronous colorectal carcinoma and a germline MSH2 mutation
    Canney, A.
    Sheahan, K.
    Keegan, D.
    Tolan, M.
    Hyland, J.
    Green, A.
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2009, 62 (05) : 471 - 473
  • [4] Surgery, wound healing, and metastasis: Recent insights and clinical implications
    Ceelen, Wim
    Pattyn, Piet
    Mareel, Marc
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 89 (01) : 16 - 26
  • [5] Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors
    Gylling, A. H. S.
    Nieminen, T. T.
    Abdel-Rahman, W. M.
    Nuorva, K.
    Juhola, M.
    Joensuu, E. I.
    Jarvinen, H. J.
    Mecklin, J. -P.
    Aarnio, M.
    Peltomaki, P. T.
    [J]. CARCINOGENESIS, 2008, 29 (07) : 1351 - 1359
  • [6] EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Hastings, K.
    Yu, H. A.
    Wei, W.
    Sanchez-Vega, F.
    DeVeaux, M.
    Choi, J.
    Rizvi, H.
    Lisberg, A.
    Truini, A.
    Lydon, C. A.
    Liu, Z.
    Henick, B. S.
    Wurtz, A.
    Cai, G.
    Plodkowski, A. J.
    Long, N. M.
    Halpenny, D. F.
    Killam, J.
    Oliva, I
    Schultz, N.
    Riely, G. J.
    Arcila, M. E.
    Ladanyi, M.
    Zelterman, D.
    Herbst, R. S.
    Goldberg, S. B.
    Awad, M. M.
    Garon, E. B.
    Gettinger, S.
    Hellmann, M. D.
    Politi, K.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (08) : 1311 - 1320
  • [7] Identification of a Microsatellite Stable, EGFR-Mutant Lung Adenocarcinoma Developing in a Patient With Lynch Syndrome
    Hissong, Erika
    Baek, Inji
    Costa, Victoria
    Beneck, Debra
    Saxena, Ashish
    Solomon, James P.
    Song, Wei
    [J]. JCO PRECISION ONCOLOGY, 2020, 4 : 818 - 822
  • [8] Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20107, 10.3322/caac.21492, 10.3322/caac.20115]
  • [9] Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data
    Jemielita, Thomas
    Li, Xiaoyun
    Piperdi, Bilal
    Zhou, Wei
    Burke, Thomas
    Chen, Cong
    [J]. JCO CLINICAL CANCER INFORMATICS, 2021, 5 : 56 - 65
  • [10] Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
    Kawashima, Yosuke
    Nishikawa, Shingo
    Ninomiya, Hironori
    Yoshida, Reiko
    Takano, Natsuki
    Oguri, Tomoyo
    Kitazono, Satoru
    Yanagitani, Noriko
    Horiike, Atsushi
    Ohyanagi, Fumiyoshi
    Ishikawa, Yuichi
    Nishio, Makoto
    [J]. INTERNAL MEDICINE, 2019, 58 (10) : 1479 - 1484